¼¿ï¾Æ»êº´¿ø ´ëÇѺÎÀÎÁ¾¾ç¿¬±¸È¸ KGOG 2019 Summer Workshop Cervical Cancer : 2019-08-11±³À°ÀÏÀÚ : 2019-08-11
±³À°Àå¼Ò : ¼¿ï¾Æ»êº´¿ø ¿¬±¸¿ø ÁöÇÏ´ë°´ç
±³À°ÁÖÁ¦ :
KGOG 2019 Summer Workshop Cervical CancerÁÖÃÖ±â°ü : ´ëÇѺÎÀÎÁ¾¾çÇÐȸ
½ÃÇà±â°ü(ÁöºÎ/°ú) : ´ëÇѺÎÀÎÁ¾¾ç¿¬±¸È¸
´ã´çÀÚ : KGOG
¿¬¶ôó : 02-512-5420
À̸ÞÀÏ :
koreagynonco@hanmail.net ±³À°Á¾·ù : »êºÎÀΰú
Âü¼®¿¹»óÀοø : 150¸í
Èñ¸ÁÆòÁ¡ : 6Á¡
Áö¿ª :
¼¿ïƯº°½Ã±³À°½Ã°£ : 6 ½Ã°£ 15ºÐ
¼¼ºÎ¼ö°·á : 30,000¿ø
ºñ°í
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 08-11 ¼¿ï¾Æ»êº´¿ø¿¬±¸¿øÁöÇÏ´ë°´ç 08:55~09:00 Orientation ±è´ë¿¬(¿ï»êÀÇ´ë)
±³À°½Ã°£ 08-11 ¼¿ï¾Æ»êº´¿ø¿¬±¸¿øÁöÇÏ´ë°´ç 09:00~09:10 KGOG ÀڱðæºÎ¾Ï ÀÓ»ó½ÃÇè º¸°í ±è´ë¿¬(¿ï»êÀÇ´ë)
±³À°½Ã°£ 08-11 ¼¿ï¾Æ»êº´¿ø¿¬±¸¿øÁöÇÏ´ë°´ç 09:10~09:20 NRG, GCIG ÀڱðæºÎ¾Ï ÀÓ»ó½ÃÇè º¸°í ±è¹®È«(¿øÀÚ·ÂÀÇÇпø)
±³À°½Ã°£ 08-11 ¼¿ï¾Æ»êº´¿ø¿¬±¸¿øÁöÇÏ´ë°´ç 09:20~09:40 2018 Revised FIGO staging: impact on clinical practice ³ëÁÖ¿ø(µ¿±¹ÀÇ´ë)
±³À°½Ã°£ 08-11 ¼¿ï¾Æ»êº´¿ø¿¬±¸¿øÁöÇÏ´ë°´ç 09:40~10:00 The updates in early cervical cancer treatment ÃÖöÈÆ(¼º±Õ°üÀÇ´ë)
±³À°½Ã°£ 08-11 ¼¿ï¾Æ»êº´¿ø¿¬±¸¿øÁöÇÏ´ë°´ç 10:00~10:20 The updates in locally advanced cervical cancer treatment ¹é¹ÎÇö(ÇѸ²ÀÇ´ë)
±³À°½Ã°£ 08-11 ¼¿ï¾Æ»êº´¿ø¿¬±¸¿øÁöÇÏ´ë°´ç 10:20~10:40 The updates in recurrent, metastatic cervical cancer treatment À̼ºÁ¾(°¡Å縯ÀÇ´ë)
Åä·Ð 08-11 ¼¿ï¾Æ»êº´¿ø¿¬±¸¿øÁöÇÏ´ë°´ç 10:40~10:50 Discussion ()
±³À°½Ã°£ 08-11 ¼¿ï¾Æ»êº´¿ø¿¬±¸¿øÁöÇÏ´ë°´ç 11:00~11:30 Current status of clinical trials in JGOG TBD(Japan)
±³À°½Ã°£ 08-11 ¼¿ï¾Æ»êº´¿ø¿¬±¸¿øÁöÇÏ´ë°´ç 11:30~11:50 Current status of translational research in JGOG TBD(Japan)
Åä·Ð 08-11 ¼¿ï¾Æ»êº´¿ø¿¬±¸¿øÁöÇÏ´ë°´ç 11:50~12:00 Discussion ()
±³À°½Ã°£ 08-11 ¼¿ï¾Æ»êº´¿ø¿¬±¸¿øÁöÇÏ´ë°´ç 13:40~14:00 Current status of clinical trial using by BLS-ILB-E710c (HPV 16 E7 Ag-expressing L. casei vaccine) in patients with CIN 2/3. ¼Û½ÂÈÆ(Â÷ÀÇ´ë)
±³À°½Ã°£ 08-11 ¼¿ï¾Æ»êº´¿ø¿¬±¸¿øÁöÇÏ´ë°´ç 14:00~14:20 Clearance of persistent HPV infection and cervical lesion by GX-188E (therapeutic DNA vaccine) in CIN3 patients (Genexine)
±³À°½Ã°£ 08-11 ¼¿ï¾Æ»êº´¿ø¿¬±¸¿øÁöÇÏ´ë°´ç 14:20~14:40 Clinical trial tropical EGCG (Veregen¢ç) targeting cervical dysplasia and HPV infection: UWCCC Chemoprevention Consortium of US-NCI ÀÌ¿µÀç(¿ï»êÀÇ´ë)
Åä·Ð 08-11 ¼¿ï¾Æ»êº´¿ø¿¬±¸¿øÁöÇÏ´ë°´ç 14:40~14:50 Discussion ()
±³À°½Ã°£ 08-11 ¼¿ï¾Æ»êº´¿ø¿¬±¸¿øÁöÇÏ´ë°´ç 15:10~15:30 Recent updates in cervical cancer immunotherapy ¹Ú¿µÇÑ(ÇѸ²ÀÇ´ë)
±³À°½Ã°£ 08-11 ¼¿ï¾Æ»êº´¿ø¿¬±¸¿øÁöÇÏ´ë°´ç 15:30~15:50 Real world experience of Pembrolizumab for cervical cancer patients ÃÖ¹Îö(Â÷ÀÇ´ë)
±³À°½Ã°£ 08-11 ¼¿ï¾Æ»êº´¿ø¿¬±¸¿øÁöÇÏ´ë°´ç 15:50~16:10 iRECIST: A clarification of tumour response assessment in the immunotherapy era ±è°æ¿ø(¿ï»êÀÇ´ë)
Åä·Ð 08-11 ¼¿ï¾Æ»êº´¿ø¿¬±¸¿øÁöÇÏ´ë°´ç 16:10~16:20 Discussion ()
±³À°½Ã°£ 08-11 ¼¿ï¾Æ»êº´¿ø¿¬±¸¿øÁöÇÏ´ë°´ç 16:20~16:30 CX1902 Àç¹ß¼º, ÁøÇ༺, ÀüÀ̼º ÀڱðæºÎ¾Ï¿¡¼ Ç×¾ÏÁ¦-¾Æ¹Ù½ºÆ¾ º´ÇÕ¿ä¹ýÀÇ ¾ÈÀü¼º ¹× È¿°úÆò°¡¸¦ À§ÇÑ ´Ù±â°ü ÈÄÇâÀû ÄÚȣƮ ±¸Ãà ¿¬±¸ ÀÓ¸íö(±¹¸³¾Ï¼¾ÅÍ)
Åä·Ð 08-11 ¼¿ï¾Æ»êº´¿ø¿¬±¸¿øÁöÇÏ´ë°´ç 16:30~16:35 Discussion ()
±³À°½Ã°£ 08-11 ¼¿ï¾Æ»êº´¿ø¿¬±¸¿øÁöÇÏ´ë°´ç 16:35~16:45 CX1903 MIS vs Open Surgery in Early cervical cancer Study (MOSES) ¹ÚÁ¤¿(¿ï»êÀÇ´ë)
Åä·Ð 08-11 ¼¿ï¾Æ»êº´¿ø¿¬±¸¿øÁöÇÏ´ë°´ç 16:45~16:50 Discussion ()
±³À°½Ã°£ 08-11 ¼¿ï¾Æ»êº´¿ø¿¬±¸¿øÁöÇÏ´ë°´ç 16:50~17:00 CX1904 Therapeutic effect of surgical debulking of metastatic lymph nodes in cervical cancer stage IIIC ³ëÁÖ¿ø(µ¿±¹ÀÇ´ë)
Åä·Ð 08-11 ¼¿ï¾Æ»êº´¿ø¿¬±¸¿øÁöÇÏ´ë°´ç 17:00~17:05 Discussion ()
±³À°½Ã°£ 08-11 ¼¿ï¾Æ»êº´¿ø¿¬±¸¿øÁöÇÏ´ë°´ç 17:05~17:15 CX1905 Korean radical Tachelectomy of cerviX cancer assessment study (KTX) ±èÁÖÇö(¿ï»êÀÇ´ë)
Åä·Ð 08-11 ¼¿ï¾Æ»êº´¿ø¿¬±¸¿øÁöÇÏ´ë°´ç 17:15~17:20 Discussion ()